The final, formatted version of the article will be published soon.
REVIEW article
Front. Oncol.
Sec. Cancer Metabolism
Volume 15 - 2025 |
doi: 10.3389/fonc.2025.1521558
Prognostic value of circulating Chromogranin A in prostate cancer: a systematic review and meta-analysis
Provisionally accepted- Department of Urology, First Affiliated Hospital of Chongqing Medical University, Chongqing, China
Background: There are discrepancies between the results of different studies regarding the prognostic role of circulating Chromogranin A (CgA) in prostate cancer. Therefore, we conducted a meta-analysis of the available findings to explore the value of circulating Chromogranin A in the prognosis of prostate cancer.Methods: We systematically searched the PubMed, Embase, Web of Science, Cochrane Library, and Clinical Trials databases for studies on the relationship between CgA and survival outcomes in prostate cancer from inception until November 2023, and we focused on articles detecting circulating CgA, with the primary endpoints of the studies being overall survival (OS), and progression-free survival (PFS).Results: Of the 2049 articles retrieved, 10 articles met our inclusion criteria, involving a total of 1445 patients. Elevated circulating CgA was associated with poorer OS (HR=1.82, 95% CI: 1.38–2.41; p<0.001) and PFS (HR=2.04, 95% CI: 1.42–2.94; p<0.001). However, no correlation was found between post-treatment circulating CgA changes and OS (HR=0.95, 95% CI: 0.66–1.37; p=0.767).Conclusion: Circulating CgA is a predictive marker of poor survival outcomes in prostate cancer However, the sample size of the current study is small and larger studies are needed to further validate this in the future.
Keywords: prostat cancer, circulating Chromogranin A, neuroendocrine, Meta-analysis, prognostic
Received: 02 Nov 2024; Accepted: 20 Jan 2025.
Copyright: © 2025 Tang, Liu, Song, Zhu, Su and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xiaoying Tang, Department of Urology, First Affiliated Hospital of Chongqing Medical University, Chongqing, China
Liangdong Song, Department of Urology, First Affiliated Hospital of Chongqing Medical University, Chongqing, China
Shuai Su, Department of Urology, First Affiliated Hospital of Chongqing Medical University, Chongqing, China
Delin Wang, Department of Urology, First Affiliated Hospital of Chongqing Medical University, Chongqing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.